BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...joining first-time backers GV and Alexandria Venture Investments and returning investors Arch Venture Partners, Biomatics Capital, Decheng Capital...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi Ventures, Takeda Ventures and Decheng Capital...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...in the U.S. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure,” Decheng Capital’s...
...said. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure.” Victor Tong, Decheng Capital...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

...Global Investors and Wellington Management Company, as well as existing investors Arix Bioscience plc (LSE:ARIX), Decheng Capital...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...company Cue Health Inc. raised $100 million in a series C, which saw participation from Decheng Capital...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital...
...Inc. Merck & Co. Inc. Society for Immunotherapy of Cancer Longitude Capital Novo Holdings A/S Sofinnova Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...led its $260 million series C-2 equity round, which also included RA Capital, Hillhouse Capital, Decheng Capital...
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital...
BioCentury | Jan 30, 2020
Preclinical News

Mammoth eyes CRISPR-based therapeutics with new funding

...With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...a series C round led by Madrone Capital Partners with participation by Arch Venture Partners, Decheng Capital...
...investors. The company will use the funds to develop and commercialize its DNA sequencing platform. Decheng Capital...
Items per page:
1 - 10 of 63
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...joining first-time backers GV and Alexandria Venture Investments and returning investors Arch Venture Partners, Biomatics Capital, Decheng Capital...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi Ventures, Takeda Ventures and Decheng Capital...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

...in the U.S. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure,” Decheng Capital’s...
...said. “China has definitely demonstrated more forward thinking with regard to healthcare expenditure.” Victor Tong, Decheng Capital...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

...Global Investors and Wellington Management Company, as well as existing investors Arix Bioscience plc (LSE:ARIX), Decheng Capital...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

...company Cue Health Inc. raised $100 million in a series C, which saw participation from Decheng Capital...
BioCentury | Jun 11, 2020
Finance

Checkmate raises $85M series C to support new indications for TLR9 agonist

...Cancer Society, as well as existing investors Sofinnova Investments, venBio Partners, F-Prime Capital Partners, and Decheng Capital...
...Inc. Merck & Co. Inc. Society for Immunotherapy of Cancer Longitude Capital Novo Holdings A/S Sofinnova Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...led its $260 million series C-2 equity round, which also included RA Capital, Hillhouse Capital, Decheng Capital...
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital...
BioCentury | Jan 30, 2020
Preclinical News

Mammoth eyes CRISPR-based therapeutics with new funding

...With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...a series C round led by Madrone Capital Partners with participation by Arch Venture Partners, Decheng Capital...
...investors. The company will use the funds to develop and commercialize its DNA sequencing platform. Decheng Capital...
Items per page:
1 - 10 of 63